 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C25H39NO3 |
| Molar mass | 401.591 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Cetilistat is a drug designed to treatobesity. It acts in the same way as the older drugorlistat (Xenical) by inhibitingpancreatic lipase, anenzyme that breaks downtriglycerides in theintestine. Without this enzyme, triglycerides from the diet are prevented from beinghydrolyzed into absorbable freefatty acids and are excreted undigested.[1]
In human trials from 2007, cetilistat was shown to produce similar weight loss to orlistat, but also produced similar side effects such as oily, loose stools,fecal incontinence, frequent bowel movements, andflatulence.[2][3] It is likely that the same precautions would apply in that absorption offat-soluble vitamins and other fat-soluble nutrients may be inhibited, requiring vitamin supplements to be used to avoid deficiencies.
Cetilistat completed Phase 1 and 2 trials in the West and as of 2009 was in Phase 3 trials in Japan where it was partnered withTakeda.[4] Norgine BV acquired the full global rights to cetilistat from Alizyme after the latter went into administration.[5][needs update]
In 2010, a phase 2 trial found cetilistat significantly reduced weight and was better tolerated thanorlistat.[6]
Takeda gained approval to market Cetilistat in Japan, but terminated the license agreement with Norgine in 2018.[7]
